OPTICAL CHERENKOV IMAGING DOSIMETRY IN HUMAN RADIOTHERAPY

人体放射治疗中的光学契伦科夫成像剂量测定

• 批准号: 10560892
• 负责人: David J. Gladstone
• 金额: $ 57.74万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10560892
• 关键词: 3-Dimensional; Accreditation; Advanced Development; Archives; Area; Breast; Calibration; Chronic; Clinical; Clinical Management; Complex; Core Grant; Data; Deposition; Development; Doctor of Philosophy; Dose; Dose Rate; Electrons; Embryo; Engineering; Fatty acid glycerol esters; Funding; Geometry; Grant; Human; Image; Image Analysis; Imaging Device; Imaging technology; Institution; Leadership; Legal patent; Light; Linear Accelerator Radiotherapy Systems; Maps; Medical; Medicine; Methodology; Methods; Noise; Norris Cotton Cancer Center; Optics; Patient imaging; Patients; Physics; Physiologic pulse; Positioning Attribute; Property; Protons; Publications; Radiation; Radiation Dose Unit; Radiation Oncology; Radiation therapy; Recording of previous events; Research; Research Project Grants; Resources; Role; Scanning; Schools; Science; Shapes; Signal Transduction; Skin; Somatotype; Surface; System; Techniques; Technology; Testing; Therapeutic; Time; Tissues; Visual; Visualization; Work; animation; base; cherenkov imaging; clinically relevant; commercialization; design; dosimetry; experience; human imaging; human tissue; imaging facilities; imaging system; improved; innovation; oncology program; optical imaging; programs; quantitative imaging; real-time images; skin color; success; technology development; technology platform; timeline; tool; treatment center; treatment planning; visual map

ABSTRACT Optical imaging of Cherenkov emission from tissue during radiotherapy has been demonstrated in humans, providing a map correlated to radiation dose within the surface tissues. In external beam radiotherapy, the signal is optimally captured by time-gated intensified cameras, synchronized to the linear accelerator pulses, allowing rejection of the majority of background room light, and providing real time video of each radiotherapy treatment with standard dose rates. This discovery combined with CT and reflectance calibration has the potential to allow accurate quantitative dose imaging in humans for the first time in the history of therapeutic radiation use. While the imaging technology has inherent limitations to surface regions, the fact that it is a real time imaging tool and provide visual recording of every feature of a treatment plan is revolutionary. It has the potential for a paradigm change in how radiotherapy is documented and archived for daily reliance, quality audit and potentially automated control of delivery. The implementation of Cherenkov imaging is significantly simpler than most dosimetry tools, however the understanding and interpretation of the images need to be established, in order to be clear about what is possible in imaging delivery of dose. This proposed technology developments advance the methods for quantitative dose imaging in whole breast radiation treatment using our patented approach to CT/reflectance calibration of Cherenkov imaging, will be advanced and tested in regular treatments. Additionally, we will advance the ability to image patients with complex multi-field treatments, where adjacent beam fields are matched, so that we can quantify the dose accuracy at the match lines. Another application is treatment of total skin with electron therapy, where the field is extremely large and so imaging dosimetry makes sense. Our preliminary data indicates that areas of chronic underexposure exist today and the optimal delivery technique will be defined by our efforts in imaging and 3D animation & visualization of total body skin dose, developing an optimized imaging system to identify the ideal treatment technique for patients of different body shape. Finally, Cherenkov imaging is synergistic with scintillator imaging of dose, and this will be advanced as a related tool to remotely quantify skin dose. Taken together, this project will advance the only way to directly image radiotherapy dose and delivery on the patient’s tissue. The core of the project is combined technology systems, leveraging a large installed base of cameras and national partnerships advancing this field. This technology is embryonic but on the cusp of commercialization, where the focus of this research project being to advance the science and methods of where it can add value to radiotherapy. The long term benefit of advancing this technology will be to change the way in which radiotherapy incidents are observed by the therapist team and have these recorded on a daily basis in every treatment center.

摘要 在放射治疗期间来自组织的切伦科夫发射的光学成像已经在人体中得到证实， 提供与所述表面组织内的辐射剂量相关的图。在体外放射治疗中， 由时间门控增强相机最佳地捕获，与线性加速器脉冲同步， 拒绝大部分的背景室光，并提供每个放射治疗的真实的时间视频 使用标准剂量率这一发现与CT和反射率校准相结合， 在放射治疗使用的历史上，这是第一次在人体中进行精确的定量剂量成像。而 成像技术对于表面区域具有固有的局限性，事实上，它是真实的时间成像工具， 为治疗计划的每个特征提供可视记录是革命性的。它有可能成为 放射治疗的记录和存档方式发生变化，以供日常依赖、质量审核和潜在的 自动控制交付。切伦科夫成像的实施比大多数方法要简单得多 剂量测定工具，但需要建立对图像的理解和解释，以便 清楚在剂量的成像输送中什么是可能的。这一技术发展的进步， 在全乳房放射治疗中使用我们的专利方法进行定量剂量成像的方法， 切伦科夫成像的CT/反射率校准将在常规治疗中进行改进和测试。此外，本发明还 我们将提高用复杂的多射野治疗对患者进行成像的能力， 匹配，以便我们可以量化匹配线处的剂量准确度。另一个应用是治疗全 皮肤与电子治疗，其中领域是非常大的，所以成像剂量是有意义的。我们 初步数据表明，目前存在慢性放射性不足的地区， 将通过我们在成像和3D动画以及全身皮肤剂量可视化方面的努力来定义， 优化成像系统，为不同体型的患者确定理想的治疗技术。最后， 切伦科夫成像与闪烁体剂量成像具有协同作用，这将作为一种相关工具， 远程量化皮肤剂量综上所述，该项目将推进直接成像放射治疗的唯一途径 剂量和输送到患者的组织上。该项目的核心是组合技术系统，利用 庞大的摄像机安装基础和国家合作伙伴关系推动了这一领域的发展。这项技术还处于萌芽阶段， 在商业化的风口浪尖上，这个研究项目的重点是推进科学， 它可以为放射治疗增加价值的方法。推进这项技术的长期利益将是 改变治疗师团队观察放射治疗事件的方式，并将其记录在 在每个治疗中心每天都有。

项目成果

Radiotherapy-induced Cherenkov luminescence imaging in a human body phantom.

• DOI: 10.1117/1.jbo.23.3.030504
• 发表时间: 2018-03
• 期刊: Journal of biomedical optics
• 影响因子: 3.5
• 作者: Ahmed SR;Jia JM;Bruza P;Vinogradov S;Jiang S;Gladstone DJ;Jarvis LA;Pogue BW
• 通讯作者: Pogue BW

Photon-limited Cherenkov imaging of radiation therapy dose.

放射治疗剂量的光子限制切伦科夫成像。

• DOI: 10.1364/ol.485668
• 发表时间: 2023
• 期刊: Optics letters
• 影响因子: 3.6
• 作者: Jia,Mengyu;Sun,Boshuai;Wang,Yuxia;Gao,Feng;Yuan,Zhiyong;Pogue,BrianW
• 通讯作者: Pogue,BrianW

Non-contact scintillator imaging dosimetry for total body irradiation in radiotherapy.

放射治疗中全身照射的非接触式闪烁体成像剂量测定。

• DOI: 10.1088/1361-6560/ad1a23
• 发表时间: 2024
• 期刊: Physics in medicine and biology
• 影响因子: 3.5
• 作者: Niver,AlexanderP;Hammer,CliffordG;Culberson,WesleyS;Jacqmin,Dustin;Pogue,BrianW
• 通讯作者: Pogue,BrianW

Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells.

分化增强了LNCAP前列腺癌细胞的氨基乙烯酸依赖性光动力治疗。

• DOI: 10.1038/sj.bjc.6600575
• 发表时间: 2002-11-18
• 期刊: BRITISH JOURNAL OF CANCER
• 影响因子: 8.8
• 作者: Ortel, B;Sharlin, D;O'Donnell, D;Sinha, AK;Maytin, EV;Hasan, T
• 通讯作者: Hasan, T

Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.

光化性角化病病变中治疗前原卟啉 IX 浓度可能是对基于氨基乙酰丙酸的光动力疗法反应的预测生物标志物。

• DOI: 10.1016/j.pdpdt.2015.10.006
• 发表时间: 2015
• 期刊: Photodiagnosis and photodynamic therapy
• 影响因子: 3.3
• 作者: Kanick,SC;Davis,SC;Zhao,Y;Sheehan,KL;Hasan,T;Maytin,EV;Pogue,BW;Chapman,MS
• 通讯作者: Chapman,MS